Anti‐tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL‐302 in neuroblastoma
Abstract The PI3K pathway is a major driver of cancer progression. However, clinical resistance to PI3K inhibition is common. IBL‐302 is a novel highly specific triple PIM, PI3K, and mTOR inhibitor. Screening IBL‐302 in over 700 cell lines representing 47 tumor types identified neuroblastoma as a st...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-08-01
|
| Series: | EMBO Molecular Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.15252/emmm.201810058 |
Search Result 1
by Sofie Mohlin, Karin Hansson, Katarzyna Radke, Sonia Martinez, Carmen Blanco‐Aparicio, Cristian Garcia‐Ruiz, Charlotte Welinder, Javanshir Esfandyari, Michael O'Neill, Joaquin Pastor, Kristoffer vonStedingk, Daniel Bexell
Published 2020-01-01
Get full textPublished 2020-01-01
Article